IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
High Throughput Screening of Potential Inhibitors of Alzheimer’s Disease Associated Tau Aggregation Protein

Author: SANTOSH JHA, ARCHANA RAI, AND HARE RAM SINGH , ARCHANA RAI
Abstract: The bioinformatics approach towards finding a solution for the problem of tau aggregation in brain requires the computational modelling of the tau aggregation protein and screening of its potential inhibitor. This was achieved in this study through a number of steps, the first being the modelling of Tau aggregation protein which has no significant template available. Thus the need of a web server such as I-TASSER which performs sequence analysis to structure of a given query protein using threading as principle, arose. The predicted model further underwent docking with total 73 confirmations of 5 already identified inhibitors. The docking results were quite promising based on the docking score and glide score although the model produced did not pass the stereotype tests of being the correct predicted structure. These inhibitors can be used as lead molecules for the designing of inhibitor based drugs. The ADMET analysis provided an insight into how good an anthraquinone can be as a drug molecule to inhibit the aggregation of PHFs. This included Lipinski’s rule, Jorgensen’s rule, blood brain barrier penetration, skin permeability, human intestinal absorption, and oral absorption. PHF 005 (1-phenyl-1-(2,3,4-trihydroxy-phenyl)-methanone) was found to be the best inhibitor of Tau protein (isoform 2) among all the inhibitors with comparable ADMET properties. So it may have to potential to be able to inhibit tau aggregation and thus add in the aid of Alzheimer’s disease. Present study focuses on the importance of structure based in silico drug design which takes less time and is cost effective.
Keyword: Tau aggregation, ADMET, Lipinski’s rule, Jorgensen’s rule.
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free